AR005277A1 - Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos. - Google Patents
Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos.Info
- Publication number
- AR005277A1 AR005277A1 ARP960105894A ARP960105894A AR005277A1 AR 005277 A1 AR005277 A1 AR 005277A1 AR P960105894 A ARP960105894 A AR P960105894A AR P960105894 A ARP960105894 A AR P960105894A AR 005277 A1 AR005277 A1 AR 005277A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- derivatives
- substituted
- alkyloxy
- hydroxy
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000005332 alkyl sulfoxy group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 102100024304 Protachykinin-1 Human genes 0.000 abstract 1
- 101800003906 Substance P Proteins 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Derivados de piperidina 1-(piperidinil 1,2-disustituido)-4-sustituidos de la fórmula (I), las formas de N-óxido, las sales de adición farmacéuticamenteaceptables y las formas estereoquímicamente isoméricas de los mismos en los cuales n es 0, 1o 2; m es 1 o 2, siempre que si m es 2, n sea 1; p es 0, 1 o2; Q es O o NR3; X es un enlace covalente o un radical bivalente de la fórmula -O, -S-, NR3-; R1 es Ar1 alquilo C1-6 o di(Ar1)alquilo C1-6, donde cada grupoalquilo C1-C6 está optativamentesustituido con hidroxi, alquiloxi C1-C4, oxo o un sustituyente oxo cetalizado de la fórmula -O-CH2-CH2-O o -O-CH2-CH2-CH2-O-; R2 es Ar2, Ar2 alquilo C1-6, Het o Het alquilo C1-6; R3 es hidrógeno o alquilo C1-C6; R4 es hidrógeno, alquilo C1-C4, alquiloxi C1-C4 alquilo C1-C4,hidroxi-alquilo C1-C4, carboxilo, alquiloxicarbonilo C1-C4 o Ar3; R5 es hidrógeno, hidroxi, Ar3, Ar3 alcoxi C1-6, di(Ar3)alquiloxi C1-6, Ar3 alquiltioC1-6, Ar3 alquilsulfoxi C1-6, di(Ar3)alquilsulfoxi C1-6, Ar3alquilsulfonilo C1-6, di(Ar3)alquilsulfonilo C1-6; -NR7R8, alquilo C1-6 sustituido con -NR7R8,o un radical de la fórmula (a-1) o (a-2); R4 y R5 también pueden tomados juntos; R6 es hidrógeno, hidroxi, alquiloxi C1-6, alquilo C1-C6 o Ar3 alquiloC1-6; Ar1, Ar2 y Ar3 son fenilo o fenilo sustituido; Ar2 es igualmente naftalenilo; y Het es un heterocíclico monocíclico o bicíclico optativamentesustituido; como antagonistas de la sustancia P; su proceso de preparación, composiciones que los contienen, su proceso de preparación y su uso comomedicamento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95203651 | 1995-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005277A1 true AR005277A1 (es) | 1999-04-28 |
Family
ID=8221023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960105894A AR005277A1 (es) | 1995-12-27 | 1996-12-26 | Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6169097B1 (es) |
| EP (1) | EP0855999B1 (es) |
| JP (1) | JP4039691B2 (es) |
| KR (1) | KR100493574B1 (es) |
| CN (1) | CN1131854C (es) |
| AR (1) | AR005277A1 (es) |
| AT (1) | ATE206397T1 (es) |
| AU (1) | AU707037B2 (es) |
| BR (1) | BR9612334A (es) |
| CA (1) | CA2238818C (es) |
| CZ (1) | CZ296316B6 (es) |
| DE (1) | DE69615700T2 (es) |
| DK (1) | DK0855999T3 (es) |
| EA (1) | EA001559B1 (es) |
| ES (1) | ES2164939T3 (es) |
| HU (1) | HU228128B1 (es) |
| IL (1) | IL124640A (es) |
| MY (1) | MY117557A (es) |
| NO (1) | NO310913B1 (es) |
| NZ (1) | NZ325843A (es) |
| PL (1) | PL192397B1 (es) |
| PT (1) | PT855999E (es) |
| SI (1) | SI0855999T1 (es) |
| SK (1) | SK283555B6 (es) |
| TR (1) | TR199801211T2 (es) |
| TW (1) | TW531537B (es) |
| WO (1) | WO1997024324A1 (es) |
| ZA (1) | ZA9610885B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| WO1999032481A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| AU2307899A (en) * | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| WO2000010545A2 (en) | 1998-08-25 | 2000-03-02 | Novartis Ag | Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| EP1140834A1 (en) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
| WO2000053582A1 (fr) * | 1999-03-05 | 2000-09-14 | Suntory Limited | COMPOSES HETEROCYCLIQUES POSSEDANT UN EFFET D'ACTIVATION DU RECEPTEUR α4β2 DE L'ACETYLCHOLINE NICOTINIQUE |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| WO2001027104A1 (en) * | 1999-10-13 | 2001-04-19 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| WO2001030348A1 (en) * | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| BR0111878A (pt) | 2000-06-30 | 2005-05-24 | Bristol Myers Squibb Co | N-ureido-(heterociclo-alquil)-piperidinas como moduladores da atividade de receptores de quimiocinas |
| US6642226B2 (en) * | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| ATE299139T1 (de) | 2001-03-29 | 2005-07-15 | Schering Corp | Ccr5 antagonisten verwendbar für die behandlung von aids |
| GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| CA2444595A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| US7307090B2 (en) * | 2001-07-02 | 2007-12-11 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| AR036366A1 (es) * | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| WO2003066589A1 (en) * | 2002-02-08 | 2003-08-14 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| RU2294927C2 (ru) * | 2002-05-29 | 2007-03-10 | Танабе Сейяку Ко., Лтд. | Производные пиперидина, способы их получения, фармацевтическая композиция на их основе, их применение и способ лечения |
| TWI283241B (en) | 2002-05-29 | 2007-07-01 | Tanabe Seiyaku Co | Novel piperidine compound |
| JP2005532361A (ja) * | 2002-06-17 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症の治療用の眼科用組成物 |
| JO2485B1 (en) * | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
| EP1720874A4 (en) * | 2004-02-24 | 2010-03-03 | Bioaxone Therapeutique Inc | 4-SUBSTITUTED PIPERIDINE DERIVATIVES |
| JO2527B1 (en) * | 2004-04-06 | 2010-03-17 | شركة جانسين فارماسوتيكا ان. في | Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines |
| JO2676B1 (en) | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| WO2006054513A1 (ja) * | 2004-11-19 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | 神経因性疼痛の予防又は治療剤 |
| ATE469159T1 (de) * | 2005-03-03 | 2010-06-15 | Janssen Pharmaceutica Nv | Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten |
| WO2006094948A1 (en) | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists |
| EP2402316A1 (en) | 2005-07-21 | 2012-01-04 | AstraZeneca AB (Publ) | Piperidine derivatives |
| EP2027086B1 (en) | 2006-05-19 | 2011-11-16 | Wyeth LLC | N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists |
| JP2010516734A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物 |
| CN102256963B (zh) * | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| CA2753205A1 (en) * | 2009-02-19 | 2010-08-26 | Vanderbilt University | Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same |
| MX346393B (es) | 2009-12-17 | 2017-03-17 | Centrexion Therapeutics Corp | Nuevos antagonistas del receptor ccr2 y usos de los mismo. |
| EP2549872B1 (en) * | 2010-03-23 | 2015-11-25 | GlaxoSmithKline LLC | Trpv4 antagonists |
| US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| US10149856B2 (en) | 2015-01-26 | 2018-12-11 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| AU2016287584B2 (en) | 2015-07-02 | 2020-03-26 | Centrexion Therapeutics Corporation | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
| US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| US10537567B2 (en) | 2017-07-11 | 2020-01-21 | BioAxone BioSciences, Inc. | Kinase inhibitors for treatment of disease |
| EP3746429B1 (en) | 2018-01-30 | 2022-03-09 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588722A (en) * | 1984-01-09 | 1986-05-13 | Janssen Pharmaceutica N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| WO1993014083A1 (en) * | 1992-01-09 | 1993-07-22 | Janssen Pharmaceutica N.V. | Pharmaceutically active substituted benzimidazole derivatives |
| WO1996002503A1 (en) | 1994-07-15 | 1996-02-01 | Meiji Seika Kabushiki Kaisha | Novel compound having platelet aggregation inhibitor effect |
| PT783490E (pt) | 1994-09-30 | 2002-06-28 | Novartis Erfind Verwalt Gmbh | Compostos de 1-acil-4-alifatilaminopiperidina |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW429256B (en) * | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
-
1996
- 1996-12-13 TW TW085115391A patent/TW531537B/zh not_active IP Right Cessation
- 1996-12-20 PL PL327441A patent/PL192397B1/pl unknown
- 1996-12-20 CA CA002238818A patent/CA2238818C/en not_active Expired - Fee Related
- 1996-12-20 DK DK96944691T patent/DK0855999T3/da active
- 1996-12-20 AU AU13084/97A patent/AU707037B2/en not_active Ceased
- 1996-12-20 TR TR1998/01211T patent/TR199801211T2/xx unknown
- 1996-12-20 HU HU9904125A patent/HU228128B1/hu not_active IP Right Cessation
- 1996-12-20 SI SI9630359T patent/SI0855999T1/xx unknown
- 1996-12-20 CZ CZ0186498A patent/CZ296316B6/cs not_active IP Right Cessation
- 1996-12-20 CN CN96199389A patent/CN1131854C/zh not_active Expired - Fee Related
- 1996-12-20 BR BR9612334A patent/BR9612334A/pt not_active IP Right Cessation
- 1996-12-20 DE DE69615700T patent/DE69615700T2/de not_active Expired - Lifetime
- 1996-12-20 ES ES96944691T patent/ES2164939T3/es not_active Expired - Lifetime
- 1996-12-20 JP JP52403197A patent/JP4039691B2/ja not_active Expired - Fee Related
- 1996-12-20 NZ NZ325843A patent/NZ325843A/xx not_active IP Right Cessation
- 1996-12-20 AT AT96944691T patent/ATE206397T1/de active
- 1996-12-20 SK SK831-98A patent/SK283555B6/sk unknown
- 1996-12-20 KR KR1019980704831A patent/KR100493574B1/ko not_active Expired - Fee Related
- 1996-12-20 EA EA199800604A patent/EA001559B1/ru not_active IP Right Cessation
- 1996-12-20 IL IL12464096A patent/IL124640A/en not_active IP Right Cessation
- 1996-12-20 WO PCT/EP1996/005883 patent/WO1997024324A1/en not_active Ceased
- 1996-12-20 PT PT96944691T patent/PT855999E/pt unknown
- 1996-12-20 EP EP96944691A patent/EP0855999B1/en not_active Expired - Lifetime
- 1996-12-23 ZA ZA9610885A patent/ZA9610885B/xx unknown
- 1996-12-26 AR ARP960105894A patent/AR005277A1/es unknown
- 1996-12-26 MY MYPI96005482A patent/MY117557A/en unknown
-
1998
- 1998-05-27 NO NO19982404A patent/NO310913B1/no not_active IP Right Cessation
- 1998-06-22 US US09/102,295 patent/US6169097B1/en not_active Expired - Lifetime
-
2000
- 2000-07-13 US US09/615,523 patent/US6346540B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR005277A1 (es) | Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos. | |
| MX9803407A (es) | Derivados de piperazina 1-(1,2-disustituido piperidinil)-4-sustituidos. | |
| AR051093A1 (es) | Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa | |
| AR002241A1 (es) | Derivado de 2,4-oxazolidinadiona, composicion farmaceutica que lo comprende y metodo de preparacion del mismo. | |
| PT97888A (pt) | Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem | |
| AR051092A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa | |
| ES2058292T3 (es) | Derivados de indol. | |
| AR018169A1 (es) | Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret | |
| BG103983A (en) | Gastrokinetic bicyclic benzamides of 3- or 4-substuituted 4-(aminomethyl)-piperidine derivatives | |
| AR012315A1 (es) | Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento. | |
| CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
| MX9206847A (es) | Derivados de indolpirrolcarbazol, proceso para su preparacion y medicamento que los contiene | |
| AR012102A1 (es) | Derivados de 2-(iminometil)amino-fenilo, su preparacion, uso de los mismos para la fabricacion de medicamentos y composiciones farmaceuticas que los contienen. | |
| MY117680A (en) | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)- piperidine derivatives | |
| AR041545A1 (es) | Derivados sustituidos de 1,4-di-piperidin-4 il-piperazina y su uso como antagonistas de neuroquininas | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| DK0478446T3 (da) | Heterocykliske alkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse | |
| AR033996A1 (es) | Una 7-oxo-piridopirimidina, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, un proceso para producir una pirimidina, un proceso para producir una piridopirimidina, y compuestos preparados mediante dichos procesos | |
| AR021662A1 (es) | Derivados de la piperazina, proceso para prepararlos. las composiciones farmaceuticas que los contienen y la utilizacion de las mismas como medicamentoso para la preparacion de medicamentos | |
| MX9302957A (es) | Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| AR046170A1 (es) | Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b | |
| MY121580A (en) | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl-and imidazopyridinyl)- piperidine derivatives | |
| MX9306310A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| NO812355L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater | |
| AR003412A1 (es) | Derivados de 1,3-dihidro-1-(fenilalquenil)-2h-imidazol-2-ona, procedimiento para su preparacion, composicion que los comprenden, procedimiento para obtenerdicha composicion y uso de dichos compuestos para preparar medicamentos. |